Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFeedback Regulatory News (FDBK)

Share Price Information for Feedback (FDBK)

Share Price is delayed by 15 minutes
Get Live Data
7.40    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.20 (2.74%)
Market Cap: £3.24m
FDBK Live PriceLast checked at - London Stock Exchange

Intraday Feedback Share Chart

Disposal

3 May 2016 12:00

RNS Number : 0664X
Feedback PLC
03 May 2016
 

3 May 2016

 

Feedback plc

("Feedback" or the "Company")

 

Disposal

 

Feedback plc (AIM: FDBK), the medical imaging software company is pleased to announce that it has agreed to sell its 50% equity interest in Stone Checker Software Ltd ('Stone Checker') to Free Association Books Limited, a company connected to one of Feedback's directors, Trevor Brown, for a cash consideration of £46,000 (the "Disposal").

 

Feedback invested £1,000 in Stone Checker in July 2015 and subsequently licensed its TexRAD software to Stone Checker for exclusive use in urolithiasis (kidney stones). On 28 September 2015, Feedback announced the intention to develop a product incorporating TexRAD for kidney stones. It was further stated that the vision of Stone Checker was to develop a composite risk stratification software product incorporating TexRAD CT texture analysis with other known clinical markers. This integrated product could potentially assist urologists and radiologists to provide better patient management and treatment decisions for improved patient outcomes.

 

Stone Checker is making good progress and is reaching the stage where it will require substantial additional investment. Feedback has already announced that it is committing significant resources in developing a lung cancer stratification tool in conjunction with Alliance Medical Group. Accordingly, although urolithiasis could be an exciting application for TexRAD, the directors of Feedback are of the opinion that they should focus investment in TexRAD's use in oncology. The sale of the equity interest in Stone Checker will generate a profit of £45,000 before expenses. Feedback will continue to receive royalty and licence payments should Stone Checker achieve commercial success. The sale proceeds will be used by Feedback for general corporate purposes.

 

Stone Checker is currently a pre-revenue company which made a loss before tax for the period ending 29 February 2016 of £154.

 

Related Party Transaction

 

Trevor Brown is a director and substantial shareholder in Feedback. Dr Balaji Ganeshan is a director of Stone Checker representing Feedback and is expected to remain a director of both Feedback and Stone Checker after the Disposal. Accordingly, the Disposal constitutes a related party transaction pursuant to Rule 13 of the AIM Rules for Companies ("AIM Rules"). The other three directors of Feedback have no direct involvement in Stone Checker and are not related to the purchaser of Feedback's holding and are therefore deemed to be independent under the AIM Rules for the purposes of considering the related party transaction (the "Independent Directors"). The Independent Directors, having consulted with Allenby Capital Limited, the Company's nominated adviser, consider that the terms of the disposal are fair and reasonable insofar as the Company's shareholders are concerned.

 

For further information, contact:

Feedback plc

Tom Charlton / Mike Hayball

Tel: 01954 718072

 

Allenby Capital Limited (Nominated Adviser and Joint Broker)

Simon Clements / James Thomas

Tel: 020 3328 5656

 

Peterhouse Corporate Finance Ltd (Joint Broker)

Lucy Williams / Duncan Vasey 

Tel: 020 7469 0936

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DISAJMMTMBAMBFF
Date   Source Headline
27th Apr 20202:00 pmRNSPrice Monitoring Extension
27th Apr 202011:05 amRNSSecond Price Monitoring Extn
27th Apr 202011:00 amRNSPrice Monitoring Extension
24th Apr 20207:00 amRNSGrant of Options
20th Apr 20207:00 amRNSBleepa rolled out at PAH NHS Trust for Covid-19
26th Mar 20203:52 pmRNSFeedback Medical to offer Bleepa for COVID-19
18th Feb 20207:00 amRNSInterim Results
3rd Feb 202012:21 pmRNSAppointment of Non-Executive Director
21st Jan 202010:30 amRNSChange of Registered Office
13th Jan 20207:00 amRNSLicence agreement with Imaging Engineering
19th Nov 20197:00 amRNSResult of AGM
18th Nov 20197:01 amRNSAGM Statement
18th Nov 20197:00 amRNSFirst Bleepa pilot study initiated with NHS Trust
24th Oct 20198:28 amRNSFinal Results: Revenue up 23%
17th Oct 20197:00 amRNSUpdate re Bleepa®
27th Sep 20192:52 pmRNSStatement re share price
4th Sep 20197:00 amRNSBleepa - the clinical messaging app - at NHS Expo
3rd Sep 20199:46 amRNSHolding(s) in Company
2nd Sep 201912:24 pmRNSHolding(s) in Company
2nd Sep 20197:00 amRNSHolding(s) in Company
30th Aug 20195:00 pmRNSTotal Voting Rights
29th Aug 20192:06 pmRNSResult of General Meeting
29th Aug 20197:00 amRNSBoard Changes
13th Aug 20192:45 pmRNSPosting of Circular and Notice of General Meeting
12th Aug 20197:00 amRNSProposed placing and subscription to raise £2m
7th Aug 201910:47 amRNSStatement re Online Commentary
26th Jul 201912:03 pmRNSBleepa - revolutionising clinical messaging
10th Jul 20197:00 amRNSOutcome of strategic review and trading update
10th Jun 20199:28 amRNSHolding(s) in Company
7th Jun 201910:07 amRNSHolding(s) in Company
25th Apr 20197:00 amRNSTrading update
9th Apr 20197:00 amRNSFeedback Medical CEO appointed Feedback plc CEO
14th Feb 20197:00 amRNSFeedback Medical appoints Dr Tom Oakley as CEO
24th Jan 20197:00 amRNSHalf-year Results
23rd Jan 20192:02 pmRNSResult of AGM
30th Nov 20185:00 pmRNSTotal Voting Rights
29th Nov 20182:37 pmRNSFinal Results
22nd Nov 201812:59 pmRNSFeedback retains industry standard certification
19th Nov 20182:56 pmRNSDirector/PDMR Shareholding
19th Nov 201811:49 amRNSHolding(s) in Company
16th Nov 20189:16 amRNSHolding(s) in Company
15th Nov 201811:35 amRNSResult of General Meeting
1st Nov 20183:11 pmRNSHolding(s) in Company
31st Oct 20185:00 pmRNSTotal Voting Rights
31st Oct 20184:15 pmRNSHolding(s) in Company
29th Oct 20182:44 pmRNSNotice of General Meeting
25th Oct 20187:00 amRNSProposed placing and subscription to raise £1.375m
22nd Oct 20187:00 amRNSExpansion of European customer base
3rd Oct 20187:00 amRNSTrading update
1st Oct 20187:00 amRNSAppointment of Joint Broker

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.